Russian Federal clinical recomendations on chronic urticaria diagnostics and treatment



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The revised recomendations on chronic urticaria diagnostics and treatment created by leading Russian experts are presented.

Full Text

Restricted Access

About the authors

I V Danilycheva

Institute of Immunology

Email: ivdanilycheva@mail.ru

N I Ilina

Institute of Immunology

L V Luss

Institute of Immunology

E S Fedenko

Institute of Immunology

A E Shulzhenko

Institute of Immunology

References

  1. Хаитов Р.М., Ильина Н.И. Аллергология и иммунология. Национальное руководство. М., «ГЭОТАР-Медиа», 2009, с. 75-98, 461-472.
  2. Аллергология. Федеральные клинические рекомендации. Главные редакторы: акад. РАН Р.М. Хаитов, проф. Н.И. Ильина. М. «Фармарус Принт Медиа». 2014, 126 с.
  3. Р.Н. Голубчикова, И.В. Данилычева. Хроническая идиопатическая крапивница. Диагностическая проблема. Рос. Аллергол. Журн. 2012, № 3, с. 3-6.
  4. Zuberbier T., Aberer W., Asero R. et al. EAACI.GA2LEN/EDF/ WAO urticaria guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, p.868-887.
  5. Saini S.S. Chronic Spontaneous Urticaria: Etiology and Pathogenesis. Immunol. Allergy Clin North Am 2014, v. 34, р. 33-52.
  6. Makris M., Maurer M. Zuberbier T. Pharmacotherapy of chronic spontaneous urticaria. Expert Opin. Pharmacother. 2013, v. 14, p. 2511-2519.
  7. Maurer M., Magerl M., Metz M., Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J. Dtsch. Dermatol Ges. 2013, v. 11, p. 971-978.
  8. Maurer M., Rosen K.E., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368, p. 924-35.
  9. Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. GA2LEN task forse report. Allergy. 2011, v. 66, p. 317-330.
  10. Kozel M.M., Mekkes J.R., Bossuyt P.M., Bos J.D. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema Arch. Dermatol. 1998, v. 134, p. 1575-1580.
  11. Buss Y.A. et all. Chronic urticaria - wich clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patientsJDDG, 2007, v. 1, p. 22-27
  12. S. J. Deacock. An approach to the patient with urticaria. Br. Society for Immunollogy, Clinical and Exeperimental Immunology. 2008, v. 153, p.151-161
  13. M. Goldenberg. Pharmaceutical Approval Update. P&T®. June 2014, v. 39 (6), p. 415-416.
  14. Martin Metz, Tatevik Ohanyan, Martin K. Church. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014,v. 73, p. 57-62
  15. Namazy J., Cabana M.D., Scheuerle A. et al. The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J.Allergy Clin. Immunol. 2015, v. 135, р. 407-412.

Copyright © Pharmarus Print Media, 2016



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies